

Special Issue

Novel Drug and Pharmaceutical Designs for Anti-Cancer Therapies

Message from the Guest Editor

Cancer is one of the most prevalent and deadly diseases worldwide. Drug new (re)repurposing is a viable strategy for discovering new drugs in approved drugs by defining new indications. We tried to summarize articles that inhibit cancer growth and are sensitive to anti-cancer drugs in vitro and in vivo, as well as explain the underlying chemoprevention patterns. We welcome articles on the development of new pharmacologically active compounds and the continued use of natural products such as synthetic and existing drugs as new drug developments. We welcome your original articles illuminating the challenges and opportunities in chemopreventive drug development. These can include new positioning of cancer therapeutics, selective optimization and reduction in side effects, sources and applications of synthetic drugs or drug metabolites as new drugs, drug delivery systems, and applications of nanomaterials. The manuscript collection will be published as a Special Issue of the journal.

Guest Editor

Prof. Dr. Yi-Chiang Hsu
School of Medicine, I-Shou University, Kaohsiung 82445, Taiwan

Deadline for manuscript submissions

closed (31 March 2025)



Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



mdpi.com/si/221181

*Current Issues in Molecular
Biology*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cimb@mdpi.com

[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)





Current Issues in Molecular Biology

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 3.7
Indexed in PubMed



[mdpi.com/journal/
cimb](https://mdpi.com/journal/cimb)



About the Journal

Message from the Editor-in-Chief

Editor-in-Chief

Prof. Dr. Madhav Bhatia

Department of Pathology and Biomedical Science, University of Otago,
Christchurch, 2 Riccarton Avenue, P.O. Box 4345, Christchurch 8140,
New Zealand

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PMC,
PubMed, Embase, CAPus / SciFinder, FSTA, AGRIS, and
other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is
provided to authors approximately 17.8 days after
submission; acceptance to publication is undertaken in 2.7
days (median values for papers published in this journal in
the first half of 2025).

Recognition of Reviewers:

APC discount vouchers, optional signed peer review, and
reviewer names are published annually in the journal.